B cells as therapeutic targets in SLE

Nature Reviews Rheumatology

Volumn 6, Issue 6, 2010, Pages 326-337

  Sanz, Ĩaki ^a   Lee, F Eun Hyung ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; BAMINERCEPT; BELIMUMAB; BORTEZOMIB; CARFILZOMIB; CD20 ANTIGEN; CD22 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD79 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR5 ANTAGONIST; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; EPRATUZUMAB; GAMMA INTERFERON ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR INTERLEUKIN 15 FUSION PROTEIN; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PROTEASOME; RECOMBINANT CYTOKINE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL KILLING; CELL SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOLOGY; DRUG TARGETING; GENETIC ANALYSIS; HUMAN; IMMUNOLOGY; INHIBITION KINETICS; LYMPHOCYTE DEPLETION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; B-LYMPHOCYTES; BIOLOGICAL THERAPY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 77953182426     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.68     Document Type: Review

References (106)

1. Manjarrez-Orduno, N., Quach, T. D. & Sanz, I. B cells and immunological tolerance. J. Invest. Dermatol. 129, 278-288 (2009).
2. Yanaba, K. et al. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223, 284-299 (2008).
3. Lund, F. E. Cytokine-producing B lymphocytes - key regulators of immunity. Curr. Opin. Immunol. 20, 332-338 (2008).
4. Lu, T. et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61, 482-487 (2009).
5. Leandro, M. J. & de la Torre, I. Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases; lessons from B cell-depletion therapy. Clin. Exp. Immunol. 157, 191-197 (2009).
6. Navarra, S. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Presented at the American College of Rheumatology 2009 Annual Scientific Meeting (2009).
7. Lovgren, T. et al. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen-and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 54, 1917-1927 (2006).
8. Sanz, I. The conundrum of B cell depletion in SLE. Nat. Rev. Rheumatol. 5, 304-305 (2009).
9. Anolik, J. H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580-3590 (2004).
10. Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741-750 (2006).
11. Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011-1016 (2008).
12. Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430 (2008).
13. Blair, P.A. et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J. Immunol. 182, 3492-3502 (2009).
14. Rafei, M. et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 15, 1038-1045 (2009).
15. Fillatreau, S., Gray, D. & Anderton, S. M. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8, 391-397 (2008).
16. Blair, P.A. et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129-140 (2010).
17. Barcellos, L. F. et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 5, el000696 (2009).
18. Clark, E. A. & Ledbetter, J. A. How does B cell depletion therapy work, and how can it be improved? Ann. Rheum. Dis. 64 (Suppl.), iv77-iv80 (2005).
19. Merrill, J. T. et al. Efficacy and safety of rituximabin moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222-233 (2010).
20. Wallace, D. New therapies in systemic lupus erythematosus - trials, troubles and tribulations - working towards a solution: part 2 - the politically incorrect version. Lupus 18, 101-103 (2009).
21. Anolik, J. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56, 3044-3056 (2007).
22. Duddy, M. et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092-6099 (2007).
23. Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004).
24. Albert, D. et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1724-1731 (2008).
25. Dass, S. et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58, 2993-2999 (2008).
26. Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011-1016 (2008).
27. Cancro, M. PThe BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann. Rheum. Dis. 65 (Suppl. 3), 34-36 (2006).
28. Sanz, I., Wei, C., Lee, F. E.-H. & Anolik, J. Phenotypic and functional heterogeneity of human memory B cells. Semin. Immunol. 20, 67-82 (2008).
29. Yazawa, N., Hamaguchi, Y., Poe, J. C. & Tedder, T. F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl Acad. Sci. USA 102, 15178-15183 (2005).
30. Jacobi, A. M. et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 67, 450-457 (2008).
31. Petri, M. et al. Clinically meaningful improvements with epratuzumab (anti-CD22 mAb targeting B-cells) in patients with moderate/severe systemic lupus erythematosus (SLE) flares: results from 2 randomized controlled trials [abstract 1087]. Arthritis Rheum. 58 (Suppl.), S571 (2008).
32. Tarasenko, T., Dean, J. A. & Bolland, S. FcγRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity 40, 409-417 (2007).
33. Xiang, Z. et al. Fc-γRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8, 419-429 (2007).
34. Moser, K. L., Kelly, J. A., Lessard, C. J. & Harley, J. B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10, 373-379 (2009).
35. Mackay, M. et al. Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J. Exp. Med. 203, 2157-2164 (2006).
36. Dhodapkar, K. M. et al. Selective blockade of the inhibitory Fey receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 204, 1359-1369 (2007).
37. Moisini, I. & Davidson, A. BAFF: a local and systemic target in autoimmune diseases. Clin. Exp. Immunol. 158, 155-163 (2009).
38. Moir, S. et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J. Exp. Med. 200, 587-600 (2004).
39. Avery, D. T. et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112, 286-297 (2003).
40. Jacobi, A. M. et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 62, 201-210 (2010).
41. Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFR Immunity 20, 441-453 (2004).
42. Liu, W. et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum. 50, 1884-1896 (2004).
43. Kalled, S. L. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18, 290-296 (2006).
44. Petri, M. et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 58, 2453-2459 (2008).
45. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
46. GlaxoSmithKline. GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus [online], http://www.gsk.com/media/pressreleases/2009/ 2009pressrelease-10121.htm (2009).
47. Anolik, J. H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580-3590 (2004).
48. Wei, C. et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178, 6624-6633 (2007).
49. Jacobi, A. M. et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 58, 1762-1773 (2008).
50. Odendahl, M. et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970-5979 (2000).
51. Dall'Era, M. et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase lb, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56, 4142-4150 (2007).
52. Dall'Era, M. & Wofsy, D. Systemic lupus erythematosus clinical trials - an interim analysis. Nat. Rev. Rheumatol. 5, 348-351 (2009).
53. Ghosh, D. & Tsokos, G. C. Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity 43, 48-55 (2010).
54. Bahjat, F. R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58, 1433-1444 (2008).
55. Ipr. Int. Immunol. 19, 509-522 (2007).
56. Barber, D. F. et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933-935 (2005).
57. Rommel, C., Camps, M. & Ji, H. PI3Kδ and PI3Ky: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191-201 (2007).
58. Li, Y. et al. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J. Immunol. 181, 2961-2972 (2008).
59. Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006).
60. Braun, D., Caramalho, I. & Demengeot, J. IFN-α/β enhances BCR-dependent B cell responses. Int. Immunol. 14, 411-419 (2002).
61. Bekeredjian-Ding, I. B. et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type IIFN. J. Immunol. 174, 4043-4050 (2005).
62. Giordani, L. et al. IFN-α amplifies human naive B cell TLR-9-mediated activation and Ig production. J. Leukoc. Biol. 86, 261-271 (2009).
63. Thibault, D. et al. Type IIFN receptor controls B cell expression of nucleic acid sensing toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res. Ther. 11, R112 (2009).
64. Barrat, F J. & Coffman, R. L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223, 271-283 (2008).
65. Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. & Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37, 3582-3586 (2007).
66. Yao, Y. et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60, 1785-1796 (2009).
67. Lenert, P., Brummel, R., Field, E. H. & Ashman, R. F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 25, 29-40 (2005).
68. Lampropoulou, V. et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180, 4763-4773 (2008).
69. Hron, J. D. & Peng, S. L. Type IIFN protects against murine lupus. J. Immunol. 173, 2134-2142 (2004).
70. Li, J. et al. Deficiency of type I interferon contributes to SLE2-associated component lupus phenotypes. Arthritis Rheum. 52, 3063-3072 (2005).
71. Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907-4916 (2006).
72. Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748-755 (2008).
73. van der Heijden, J. W. et al. The proteasome inhibitor bortezomib inhibits the release of NFKB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 27, 92-98 (2009).
74. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008).
75. Tian, J. et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167, 1081-1089 (2001).
76. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. & Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944-950 (2002).
77. Wei, B. et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc. Natl Acad. Sci. USA 102, 2010-2015 (2005).
78. Zhong, X. et al. Reciprocal generation of Th1/Th17 and Treg by B1 and B2 B cells. Eur. J. Immunol. 37, 2400-2404 (2007).
79. Hu, C.-Y et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857-3867 (2007).
80. + CD4 T cells. J. Immunol. 179, 2046-2050 (2007).
81. Evans, J. G. et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178, 7868-7878 (2007).
82. + phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650 (2008).
83. Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430 (2008).
84. Clatworthy, M. R. et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 360, 2683-2685 (2009).
85. Dass, S., Vital, E. M. & Emery, P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56, 2715-2718 (2007).
86. Yazawa, N., Hamaguchi, Y., Poe, J. C. & Tedder, T. F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl Acad. Sci. USA 102, 15178-15183 (2005).
87. Sawalha, A. H. et al. Genetic association of IL-21 polymorphisms with systemic lupus erythematosus. Ann. Rheum. Dis. 67, 458-461 (2008).
88. Ettinger, R. et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J. Immunol. 178, 2872-2882 (2007).
89. Avery, D. T. et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207, 155-171 (2010).
90. Illei, G. G. et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62, 542-552 (2010).
91. Anolik, J. H. et al. Cutting Edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol. 180, 688-692 (2008).
92. Hsu, H.-C. et al. Interleukin 17-producingT helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9, 166-175 (2008).
93. Doreau, A. et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10, 778-785 (2009).
94. Grammer, A. C. & Lipsky, P. E. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum. 46, 1417-1429 (2002).
95. Huang, W. et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46, 1554-1562 (2002). (Pubitemid 34620202)
96. Vinuesa, C. G., Sanz, I. & Cook, M. C. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9, 845-857 (2009).
97. Gaspal, F. M. C. et al. Mice deficient in 0X40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J. Immunol. 17 4, 3891-3896 (2005).
98. Murdoch, C. CXCR4: chemokine receptor extraordinaire. Immunol. Rev. 177, 175-184 (2000).
99. Nanki, T. et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 11, R149 (2009).
100. Linterman, M. A. et al. Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med. 206, 561-576 (2009).
101. Zheng, B. et al. CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum. 52, 620-626 (2005).
102. Yellin, M. et al. A phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MDX-1100, a fully human anti-CXCLlO monoclonal antibody, in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) [abstract 414]. Arthritis Rheum. 60 (Suppl.), S153 (2009).
103. Genovese, M. C. et al. Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA) - results of the phase 2B study in the TNF-IR population [abstract 417]. Arthritis Rheum. 60 (Suppl.), S154 (2009).
104. Palanichamy, A. et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182, 5982-5993 (2009).
105. Ngo, V. N. et al. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189, 403-412 (1999).
106. Allen, C. D. C., Okada. T. & Cyster, J. G. Germinal-center organization and cellular dynamics. Immunity 27, 190-202 (2007).